Fig. 1.
Fig. 1. Surviving T cells after treatement with IT. / Nonactivated (A) and PHA-activated (B) T cells were eliminated by SPV-T3a-dgA (□) and WT1-dgA (○), applied individually and in combination (▴) (half a dose each). Nonactivated and PHA-activated PBMC were incubated with various concentrations IT for 24 hours at 37°C. Following treatment, cells were washed and cultured for an additional 4 days in the presence of PHA to enable full exposure of IT toxicity. Subsequently, cells were stained with viability markers and analyzed by flow cytometry for the number of viable T cells relative to the untreated control. Data represent the mean ± SD as obtained with the PBMC of 3 healthy individuals.

Surviving T cells after treatement with IT.

Nonactivated (A) and PHA-activated (B) T cells were eliminated by SPV-T3a-dgA (□) and WT1-dgA (○), applied individually and in combination (▴) (half a dose each). Nonactivated and PHA-activated PBMC were incubated with various concentrations IT for 24 hours at 37°C. Following treatment, cells were washed and cultured for an additional 4 days in the presence of PHA to enable full exposure of IT toxicity. Subsequently, cells were stained with viability markers and analyzed by flow cytometry for the number of viable T cells relative to the untreated control. Data represent the mean ± SD as obtained with the PBMC of 3 healthy individuals.

Close Modal

or Create an Account

Close Modal
Close Modal